HSP90B2P and acquired epidermolysis bullosa: Thus, it seems that the mRNA vaccine, aside from not altering cytokine levels characteristic of T-helper lymphocyte populations and showing no changes in the levels of anti-Hsp antibodies (21) often associated with the development of autoimmune diseases (19), exhibits correlations between cytokines and anti-Hsp autoantibodies that are atypical for autoimmune conditions such as RA or EBA.